Corporate and Regional Press Releases

Please find below a list of our press releases.

19 Aug 2019

BOSTON SCIENTIFIC CLOSES ACQUISITION OF BTG PLC.

Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE:BTG) pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals.

15 Aug 2019

BTG receives Health Canada Medical Device License for the ICEfx™ Cryoablation System

BTG International Canada Inc. announced it has received a medical device license from Health Canada for the ICEfx™ Cryoablation System.

15 Aug 2019

Santé Canada accorde la licence d’instrument médical au système de cryoablation ICEfxMC de BTG

BTG International Canada Inc., filiale de la société BTG plc (BTG à la Bourse de Londres) spécialiste mondial en produits médicaux, a annoncé l’approbation par Santé Canada de son système de cryoablation ICEfxMC.

5 Aug 2019

Randomized double-blinded study to commence on DigiFab® for kidney injury related to CABG surgery
 

BTG plc today announced the start of a randomized double-blinded clinical study, initiated by researchers at the University of Maryland School of Medicine.

23 Jul 2019

Recommendations for personalised HCC treatment with Y90 TheraSphere™ published by an international multidisciplinary group

BTG plc (LSE: BTG), a global healthcare company, today announced consensus recommendations for personalised treatment for hepatocellular carcinoma (HCC) with TheraSphere™ have been published by an international multidisciplinary working group¹. In addition, data from the Dosisphere phase II dosimetry trial supports MAA SPECT/CT based prospective personalised dosimetry².

16 Jul 2019

BTG to invest in Chinese medical isotope diagnosis and treatment company Chengdu New Radiomedicine Technology

BTG International Asia Limited, a subsidiary of BTG plc (LSE: BTG) announced today that it has agreed to invest RMB 76million (approximately USD 11million) in the Chinese medical isotope diagnosis and treatment company Chengdu New Radiomedicine Technology Co., Ltd. (“CNRT”).

11 Jul 2019

NCCN issues first pediatric acute lymphoblastic leukemia guidelines, including use of Voraxaze®

BTG plc today highlighted the first publication of National Comprehensive Cancer Network (NCCN) pediatric acute lymphoblastic leukemia (ALL) guidelines including consideration of Voraxaze® (glucarpidase).

25 Jun 2019

Radioembolization treatment for primary liver cancer and metastatic liver cancer now available in Argentina

Argentina now the second South American country to offer TheraSphere™ treatment for liver cancer patients

25 Jun 2019

Radioembolization treatment for primary liver cancer and metastatic liver cancer now available in Brazil

Brazil to be the first South American country to offer TheraSphere® treatment for liver cancer patients

29 Apr 2019

Venous Leg Ulcer Registry Shows Promising Results for Varithena® Use in Wound Healing 

BTG plc today highlighted the VIEW VLU Registry interim study results, presented at the International Vein Congress in Miami, Florida. The interim findings confirm that Varithena® polidocanol injectable foam 1% shows promise in increasing the rate of wound healing.